All I can say is WOW!
2 new complete responses.
7/10 in the trial with responses beyond standard treatment expectations.
PTX-100 is going far my friends....Surely no way this doesn't go to a registrational trial later this year...Steven is modestly expanding the trial to ensure the FDA meeting later goes in our favour.
No wonder FDA expanded orphan drug status last week to include all TCL'S.
Well done team.
Ann: Continued promising results in PTX-100 TCL trial, page-8
Add to My Watchlist
What is My Watchlist?
